Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
Recruitment status was: Recruiting
RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease.
PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
|Breast Cancer Colorectal Cancer Esophageal Cancer Head and Neck Cancer Lung Cancer||Other: 18F-fluoromisonidazole Other: fluorescence angiography Other: laboratory biomarker analysis Procedure: infrared thermography Procedure: magnetic resonance imaging Procedure: therapeutic conventional surgery Radiation: [18F]-ML-10 Radiation: fludeoxyglucose F 18 Radiation: rubidium Rb-82|
|Study Design:||Primary Purpose: Diagnostic|
|Official Title:||Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation|
- Clinical, radiological, and pathological correlation
- Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)
|Study Start Date:||November 2006|
|Estimated Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
- To determine the ability of preoperative fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning in assessing tumor angiogenesis in patients with potentially operable non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.
- To determine the ability of preoperative fludeoxyglucose F 18 PET/CT scanning in assessing prognosis by means of measuring angiogenesis in these patients.
OUTLINE: All patients undergo fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) scanning for staging, tumor perfusion measurement/angiogenesis, and glucose metabolism. If staging confirms operable disease, then the patient proceeds to surgery as planned. Resected tumor tissue samples are examined for tumor angiogenesis in the various cancer types.
Some patients undergo a half-dose of rubidium Rb-82 or 18F-fluoromisonidazole or [18F]-ML-10 PET scan or fluorescence angiography. Patients with colorectal cancer undergo a CT scan for perfusion of the tumor after the staging PET/CT. Patients with breast cancer undergo infrared thermometry as well as a MRI scan for staging and to predict angiogenesis.
After completion of study therapy, patients are followed up at 1 month and then every 6 months for 5 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01254591
|University College Hospital||Recruiting|
|London, England, United Kingdom, NW1 2BU|
|Contact: Contact Person 44-207-631-1066 email@example.com|
|Principal Investigator:||Peter Ell, MD||University College London Hospitals|